Bleximenib is an investigational new drug that is being evaluated by Janssen Research & Development for the treatment of acute myeloid leukaemia (AML). It is a menin inhibitor preventing its interaction with KMT2A.
Pharmacology
Bleximenib is a selective inhibitor of menin preventing its interaction with the lysine methyltransferase KMT2A. The menin/KMT2A complex regulates gene expression in leukemia cells which keeps them in an immature state that is continually dividing.
Clinical trials Bleximenib is in phase 3 clinical trials for AML.
References